Milestone Scientific to Present at the Virtual Summer Summit on June 9th

Milestone Scientific, Inc.

Companies Mentioned:

Primary Exchange: AMEX
Under the Symbol: MLSS

$1.88

($0.0400)

-2.0833


Milestone Scientific to Present at the Virtual Summer Summit on June 9th

Wednesday, June 3, 2020 9:00 AM

ROSELAND, NJ / ACCESSWIRE / June 3, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will be presenting at the 2020 Virtual Summer Summit being held on June 9th-12th.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, is scheduled to present on Tuesday, June 9th at 11:30 a.m. Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here. One-on-one meetings will be held throughout the conference via video conference calls.

About The Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. For more information please visit www.investorsummitgroup.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.


Subscribe to alerts from Investor Network
SHARE ARTICLE